[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR10010A - Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos - Google Patents

Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos

Info

Publication number
CR10010A
CR10010A CR10010A CR10010A CR10010A CR 10010 A CR10010 A CR 10010A CR 10010 A CR10010 A CR 10010A CR 10010 A CR10010 A CR 10010A CR 10010 A CR10010 A CR 10010A
Authority
CR
Costa Rica
Prior art keywords
derivatives
benzodiazepinyl
pharmaceutical compositions
compositions containing
same
Prior art date
Application number
CR10010A
Other languages
English (en)
Inventor
Richard Anthony Brigandi
Mark Levick
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CR10010A publication Critical patent/CR10010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se dirige a métodos para tratar un trastorno neovascular ocular de un mamifero mediante la administración de derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmacéuticas que contienen los mismos. La presente invención comprende métodos para tratar un trastorno neovascular ocular mediante la administración de 5-[[4-[(2,3-Dimetil-2H-indazol-6-il) metilamino] -2-pirimidinil]amino] -2-metilbencenossulfonamida.
CR10010A 2005-11-29 2008-05-22 Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos CR10010A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29

Publications (1)

Publication Number Publication Date
CR10010A true CR10010A (es) 2008-11-03

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10010A CR10010A (es) 2005-11-29 2008-05-22 Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos

Country Status (28)

Country Link
US (1) US20080293691A1 (es)
EP (2) EP2329821B1 (es)
JP (1) JP5180834B2 (es)
KR (1) KR20080071188A (es)
CN (1) CN101370505B (es)
AT (1) ATE482708T1 (es)
AU (2) AU2006320535B2 (es)
BR (1) BRPI0619057A2 (es)
CA (1) CA2631173A1 (es)
CR (1) CR10010A (es)
CY (1) CY1111047T1 (es)
DE (1) DE602006017261D1 (es)
DK (1) DK1968594T3 (es)
EA (1) EA016227B1 (es)
ES (2) ES2392030T3 (es)
HK (1) HK1121386A1 (es)
HR (1) HRP20100559T1 (es)
IL (1) IL191027A0 (es)
MA (1) MA30044B1 (es)
MX (1) MX2008006379A (es)
MY (1) MY144750A (es)
NO (1) NO20081963L (es)
NZ (1) NZ568075A (es)
PL (1) PL1968594T3 (es)
PT (1) PT1968594E (es)
SI (1) SI1968594T1 (es)
UA (1) UA94427C2 (es)
WO (1) WO2007064752A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
CN102365109B (zh) 2009-01-29 2015-06-03 弗赛特影像4股份有限公司 后段给药
CN102573477A (zh) * 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
WO2011050159A1 (en) * 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
MY176514A (en) * 2010-10-07 2020-08-12 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
AP2013007335A0 (en) 2011-06-28 2013-12-31 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing regorafenib
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
LT2755600T (lt) 2011-09-16 2021-04-26 Forsight Vision4, Inc. Skysčio pakeitimo aparatas
AU2012332952B2 (en) 2011-10-31 2016-05-05 Novartis Ag Pazopanib formulation
JP2015500221A (ja) 2011-12-01 2015-01-05 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 眼疾患の治療および予防方法
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
CA2876311A1 (en) 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
WO2014097152A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
ES2669425T3 (es) 2012-12-17 2018-05-25 Sun Pharmaceutical Industries Limited Procedimiento para la preparación de pazopanib o sales del mismo
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
WO2015068175A2 (en) * 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
KR102256185B1 (ko) 2014-09-09 2021-05-26 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
CN110478119B (zh) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 可膨胀药物递送装置和使用方法
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
JP7183042B2 (ja) 2016-01-07 2022-12-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の免疫炎症性疾患のための治療法
EP3439591B1 (en) 2016-04-05 2020-09-23 ForSight Vision4, Inc. Implantable ocular drug delivery devices
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
ES2191719T3 (es) 1994-11-10 2003-09-16 Univ Kentucky Res Found Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
ES2232005T3 (es) 1997-08-11 2005-05-16 Allergan, Inc. Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion.
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
EP1313415B1 (en) 2000-08-30 2008-08-13 Johns Hopkins University Devices for intraocular drug delivery
KR100847169B1 (ko) * 2000-12-21 2008-07-17 글락소 그룹 리미티드 혈관형성 조절제로서의 피리미딘아민
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
PT1420716E (pt) 2001-08-29 2012-11-21 Ricardo A P De Carvalho Um sistema implantável e selável destinado à administração unidireccional de agentes terapêuticos em tecidos-alvo
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
MXPA04010132A (es) * 2002-05-03 2005-01-25 Alcon Inc Metodo para tratar trastornos vasculares mediados por el factor de crecimiento endotelial vascular.
CN1688553A (zh) * 2002-06-17 2005-10-26 史密丝克莱恩比彻姆公司 化学方法
WO2005105094A2 (en) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Cancer treatment method
CA2584305A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Also Published As

Publication number Publication date
CN101370505A (zh) 2009-02-18
NO20081963L (no) 2008-08-26
CY1111047T1 (el) 2015-06-11
AU2006320535A1 (en) 2007-06-07
CN101370505B (zh) 2012-03-21
HK1121386A1 (en) 2009-04-24
EA200801168A1 (ru) 2008-10-30
ES2392030T3 (es) 2012-12-04
WO2007064752A3 (en) 2008-08-14
US20080293691A1 (en) 2008-11-27
ATE482708T1 (de) 2010-10-15
JP2009517396A (ja) 2009-04-30
IL191027A0 (en) 2009-08-03
EA016227B1 (ru) 2012-03-30
NZ568075A (en) 2010-12-24
WO2007064752A2 (en) 2007-06-07
PL1968594T3 (pl) 2011-03-31
JP5180834B2 (ja) 2013-04-10
MY144750A (en) 2011-10-31
ES2350858T3 (es) 2011-01-27
KR20080071188A (ko) 2008-08-01
EP2329821A1 (en) 2011-06-08
AU2010249187A1 (en) 2011-01-06
PT1968594E (pt) 2010-11-18
UA94427C2 (ru) 2011-05-10
CA2631173A1 (en) 2007-06-07
EP1968594A2 (en) 2008-09-17
MA30044B1 (fr) 2008-12-01
MX2008006379A (es) 2009-03-03
AU2006320535B2 (en) 2010-09-23
EP1968594B1 (en) 2010-09-29
HRP20100559T1 (hr) 2010-11-30
BRPI0619057A2 (pt) 2011-09-20
SI1968594T1 (sl) 2011-01-31
DK1968594T3 (da) 2010-12-13
DE602006017261D1 (de) 2010-11-11
EP2329821B1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CR10010A (es) Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
TW200716139A (en) Methods and compositions for managing psychotic disorders
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
ATE500831T1 (de) Krebsbehandlungsverfahren
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
DE60034605D1 (de) Sulfonamide und deren Derivate als Modulatoren der Endothelin-Aktivität
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
UY27018A1 (es) Derivados de la pirimidina
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
ATE507226T1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
BR0005010A (pt) Composição para tratamento de distúrbios de secreção externa exceto a hipolacrimação e seu uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)